,45 The 2021 Kidney Disease: Improving Global Outcomes guidelines recommend mycophenolate mofetil (MMF) plus glucocorticoids, in addition to supportive care, as first-line therapy in patients with moderate-to-severe disease and the absence of monoclonal gammopathy, with consideration of an anti-C5 antibody in patients who fail treatment, followed by enrollment in a clinical trial.3 The gene discussed is C5; the disease is kidney disorder.